

# Biomarcatori nel Trauma Cranico Lieve: Aggiornamenti e Prospettive



Andrea Fabbri

Pronto Soccorso e Medicina  
d'Urgenza, Semi-intensiva.  
AUSL della Romagna – Forlì  
[andrea.fabbri@auslromagna.it](mailto:andrea.fabbri@auslromagna.it)



XIII congresso nazionale

**simeu**

GENOVA 30 MAG - 1 GIU 2024



# Disclaimer


- ❖ I have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
- ❖ It is the responsibility of the presenter to endorse or approve, and assume responsibility for, the content, accuracy and completeness of the information presented.



# TBI: more than one definition

Definitions of TBI vary considerably<sup>1-6</sup> resulting in difficulties in diagnosis and case ascertainment

According to the CDC<sup>5</sup>: “Traumatic brain injury (TBI) is caused by a bump, blow, or jolt to the head that disrupts the normal function of the brain”



1. Wang et al (2018). Expert Rev Mol Diag 18:165–180;
2. Maas et al (2017). Lancet Neurol 16:987–1048;
3. Carroll et al (2004). J Rehabil Med 43(Suppl):113–125;
4. Kay et al (1993). J Head Trauma Rehabil 8:86–87;
5. Centers for Disease Control and Prevention (CDC). Traumatic Brain Injury & Concussion. Available at: <https://www.cdc.gov/traumaticbraininjury/index.html>. Accessed November 2018;
6. Menon et al (2010). Arch Phys Med Rehabil 91:1637–1640.

# TBI ranges from mild to severe

## Classification of TBI severity

Criteria	Mild	Moderate	Severe
Structural imaging	Normal	Normal or abnormal	Normal or abnormal
Loss of consciousness	0–30 min	> 30 min and < 24 hrs	> 24 hrs
Alteration of consciousness / mental state	a moment up to 24 hrs	> 24 hrs Severity based on other criteria	
Post-traumatic amnesia	0-1 day	> 1 and < 7 days	> 7 days
Glasgow Coma Scale (best available score in first 24 hrs)	13–15	9–12	< 9

**Mild TBI** (a brief change in mental status or consciousness)

**Severe TBI** (an extended period of unconsciousness or memory loss)



Most TBIs that occur each year are mild, commonly called concussions<sup>2</sup>



XIII congresso nazionale

**simeu**

GENOVA 30 MAG - 1 GIU 2024

TBI, traumatic brain injury

1. O'Neil et al (2012). Complications of mild traumatic brain injury in veterans and military personnel: A Systematic Review. VA-ESP Project #05-225;
2. Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control. Report to Congress on mild traumatic brain injury in the United States: steps to prevent a serious public health problem. Atlanta (GA): Centers for Disease Control and Prevention; 2003.



# A Critical Comparison of Clinical Decision Instruments for Computed Tomographic Scanning in Mild Closed Traumatic Brain Injury in Adolescents and Adults

**Table 1.** Findings used by 7 clinical decision rules for CT scanning in mild traumatic brain injury.

Clinical Finding	Canadian	NCWFNS	New Orleans	NEXUS-II	NICE	Scandinavian
GCS score	<15 At 2 h	<15	<15	Abnormal alertness, behavior	<15 At 2 h	<15
Amnesia	Retrograde >30 min*	Any	Antegrade	—	Retrograde >30 min	Any
Suspected fracture	Open, depressed, basal	Any	Any injury above clavicles	Any	Open, depressed, basal	Basal, depressed confirmed
Vomiting	Recurrent	Any	Any	Recurrent	Recurrent	—
Age, y	≥65	—	>60	≥65	≥65 <sup>†</sup>	—
Coagulopathy	—	Any	—	Any	Any <sup>†</sup>	Any
Focal deficit	—	Any	—	Any	Any	Any
Seizure	—	History	Any	—	Any	Any
LOC	If GCS=14	Any	—	—	—	Any
Visible trauma	—	—	Above clavicles	Scalp hematoma	—	Multiple injuries
Headache	—	Any	Severe	—	—	—
Injury mechanism	Dangerous* <sup>†</sup>	—	—	—	Dangerous <sup>††</sup>	—
Intoxication	—	Abuse history	Drug, alcohol	—	—	—
Previous neurosurgery	—	Yes	—	—	—	Shunt

NCWFNS, Neurotraumatology Committee of the World Federation of Neurosurgical Societies; NICE, National Institute of Clinical Excellence; —, indicates the item not considered an indication for CT scanning by author(s) of the rule; LOC, loss of consciousness.

\*Used to determine medium risk for the Canadian Rule.

<sup>†</sup>CT scan only if also loss of consciousness or any amnesia.

<sup>††</sup>Dangerous injury mechanism=ejected from motor vehicle, pedestrian struck by motor vehicle, fall of >3 feet or 5 steps.



XIII congress

**SIMEU**

GENOVA 30 MAG - 1 GIU 2024

*Stein S, Ann Emerg Med 2009*



**CT scans rate:** Canadian CT head rule (high risk only) **53%**, Canadian **56%**, the Neurotraumatology Committee of the World Federation of Neurosurgical Societies **56%**, New Orleans **69%**, NEXUS-II **56%**, National Institute of Clinical Excellence **71%**, and the Scandinavian **50%**.

Sensitivity for any intracranial lesion **ranged from 95.7% (95% CI 93% to 97%)** (Scandinavian) to 100% (95%CI 98% to 100%) (National Institute of Clinical Excellence). Specificities varied between **30.9% (95% CI 30% to 32%)** (National Institute of Clinical Excellence) and **52.9% (95% CI 52% to 54)** (Scandinavian).

**Conclusion:** NEXUS-II and the Scandinavian clinical decision aids displayed the best combination of SE and SP. Therefore, choosing which of the 2 clinical decision instruments to use must be based on decisionmakers' attitudes toward risk.



XIII congresso nazionale

**simeu**


GENOVA 30 MAG - 1 GIU 2024






# Ionizing radiation increases cancer risk

Incidence rate ratios (IRR) for all cancer types according to number of CT scans (n=680,211)\*



IRRs for exposed vs unexposed in subset of patients with brain CT scans (n=404,105)\*



Future CT scans should be limited to situations where there is a definite clinical indication, with every scan optimized to provide a diagnostic CT image at the lowest possible radiation dose

Data are for 10.9 million children and adolescents (0–19 years old), of which 680,211 had a CT scan. \* Based on a one-year lag period.  
 † Overall cancer incidence was 24% greater for exposed vs unexposed (IRR 1.24; 95% CI 1.20–1.29). The IRR increased by 0.16 for each additional scan.  
 Mathews et al (2013). BMJ 346:f2360.

# TBI biomarkers to better understand the disease mechanism

**Facilitate early rule out**

**Predict progression and neurological outcome**

**Develop molecularly targeted therapies**



XIII congresso nazionale

**simeu**

GENOVA 30 MAG - 1 GIU 2024

TBI, traumatic brain injury



Kobeissy and Stevens, Jr. (eds.), Neuroproteomics: Methods and Protocols, Methods in Molecular Biology, vol. 1598, DOI 10.1007/978-1-4939-6952-4\_3; Chapter 3.








**Cell body injury**    **Gliosis/astroglia Injury**    **Astroglia/BBB damage**    **Tauopathy**



**pNF-H**    **SBDP150**    **SBDP120**    **MBP**  
**Axonal injury**    **Necrosis**    **Apoptosis**    **Demyelination**






# Low serum S100B levels accurately predict normal CT findings in mild TBI

- Meta-analysis of 12 clinical studies involving 2,466 pts with minor head injury
- Time from injury to S100B sampling: <3 Hrs to <24 hrs
- S100B had **high sensitivity** to predict a normal CT scan (pooled: **97%**, range 75%–100%), very high NPVs (**90%–100%**)
- Where a cutoff of 0.10 µg/L could be evaluated, sensitivities and specificities were 96% and 30%, respectively


**Conclusion:** Low serum **S100B levels accurately predict normal CT findings** after minor head injury in adults

Summary ROC curve from all 12 studies showing the relationship of sensitivity vs. 1-specificity



# S-100 in adult pts. with low-risk MHI

## Scandinavian Neurotrauma Committee recommendations





# Scandinavian guidelines incorporate the use of S100B to stratify patients for CT imaging

Undén et al. *BMC Medicine* 2013, 11:50  
<http://www.biomedcentral.com/1741-7015/11/50>



GUIDELINE

Open Access

Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update

Johan Undén<sup>1\*</sup>, Tor Ingebrigtsen<sup>2</sup> and Bertil Romner<sup>3</sup>, for the Scandinavian Neurotrauma Committee (SNC)

“We recommend that adult patients after mild head injury with GCS 14 and no risk factors (anticoagulant therapy or coagulation disorders, post-traumatic seizures, clinical signs of depressed or basal skull fracture, focal neurological deficits), or GCS 15 with loss of consciousness or repeated ( $\geq 2$ ) vomiting and no other risk factors, be sampled for analysis of S100B if less than 6 h have elapsed following trauma”

“If S100B measured within 6 hrs of mild head injury is less than 0.10  $\mu\text{g/L}$ , the patient may be discharged without a CT (moderate quality, strong recommendation)”

CT, computed tomography; GCS, Glasgow Coma Scale; h, hours; S100B, astroglial calcium-binding protein

Undén et al (2013). *BMC Medicine* 11:50.



XIII congresso nazionale

**simeu**

GENOVA 30 MAG - 1 GIU 2024



# Level C recommendation by ACEP for the use of S100B in mild TBI



TRAUMA/CLINICAL POLICY

Clinical Policy: Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting

“Level C recommendation

In mild TBI patients without significant extracranial injuries and a **serum S-100B level less than 0.1 µg/L** measured **within 4 hrs** of injury, consideration can be given to **not performing a CT.**”

Level C recommendation for the use of S100B. However, the test has no Food and Drug Administration approval for clinical use in the United States to date.



# GFAP plus UCH-L1 rule out the need for CT scan in adults with TBI with high sensitivity

The multicentre, observational **ALERT-TBI**<sup>1</sup> study (1977 adults with TBI; GCS 9–15) investigated the combination of:

GFAP (cutoff 22 pg/mL)

UCH-L1 (cutoff 327 pg/mL)

For detection of **intracranial injury**, the combination test had:

Sensitivity: **97.6%** (95% CI: 93.1–99.5%)

NPV: **99.6%** (95% CI: 98.7–99.9%)

GFAP and UCH-L1 are FDA approved for evaluation of adult patients with suspected mild TBI (GCS 13–15) when used within 12 hours of suspected head injury along with other clinical information<sup>2</sup>

# Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (**ALERT-TBI**): a multicentre observational study

	Sensitivity	Specificity	PPV	NPV
GCS 9–15 (n=1959)	0.976 (0.931–0.995)	0.364 (0.342–0.387)	0.095 (0.079–0.112)	0.996 (0.987–0.999)
GCS 14–15 (n=1920)	0.973 (0.924–0.994)	0.367 (0.345–0.390)	0.088 (0.073–0.105)	0.995 (0.987–0.999)
Neurosurgically manageable lesions (n=8)	1.00 (0.631–1.00)	0.344 (0.323–0.365)	0.006 (0.003–0.012)	1.00 (0.995–1.00)


Data in parentheses are 95% CIs. PPV=positive predictive value. NPV=negative predictive value. LRP=likelihood ratio positive. LRN=likelihood ratio negative.

**Table 3: Performance of UCH-L1 and GFAP assay for predicting intracranial injury on head CT scan**

## Interpretation

High SE and NPV of the **UCH-L1** and **GFAP** test. This supports its potential clinical role for ruling out the need for a CT scan among patients with TBI presenting at ED in whom a head CT is felt to be clinically indicated.

# Head CT images of false-negative subjects.



Sex	Age (years)	Time from injury (h)	GCS	GFAP (pg/ml)	UCH-L1 (pg/ml)	Head CT findings <sup>b</sup>
Male	62	8.9	15	16	84	Acute SDH
Female	49	5.9	15	24 <sup>a</sup>	94	SAH
Female	43	3.5	15	19	58	Parenchymal hematoma
Male	41	3.3	15	26 <sup>a</sup>	82	SAH
Male	44	2.9	13	28 <sup>a</sup>	184	SAH

# Neuroinflammatory Biomarkers for Traumatic Brain Injury Diagnosis and Prognosis: A TRACK-TBI Pilot Study

**Table 2. Markers Discriminating TBI Clinical Diagnosis and Severity**

*Clinical diagnosis: TBI vs. HC*

<i>Biomarker</i>	<i>AUC</i>	<i>TBI</i>	<i>HC</i>	<i>Sig. (p)</i>
IL-6	0.924 [0.880–0.967]	1.47 [0.55–4.07] pg/mL	0.15 [0.10–0.22] pg/mL	<0.001
IL-10	0.863 [0.804–0.922]	0.17 [0.10–0.39] pg/mL	0.05 [0.04–0.08] pg/mL	<0.001
HMGB-1	0.860 [0.802–0.919]	47.48 [24.35–146.79] ng/mL	20.77 [14.88–20.77] ng/mL	<0.001
IL-4	0.819 [0.731–0.907]	0.09 [0.07–0.15] pg/mL	0.06 [0.06–0.07] pg/mL	<0.001
IL-7	0.764 [0.637–0.891]	0.61 [0.25–1.29] pg/mL	2.32 [0.90–3.67] pg/mL	<0.001
IL-8	0.764 [0.666–0.862]	3.46 [1.53–12.58] pg/mL	1.29 [0.50–1.64] pg/mL	0.001
TARC	0.749 [0.626–0.872]	16.23 [10.49–29.74] pg/mL	40.63 [22.08–56.31] pg/mL	<0.001
IL-5	0.748 [0.621–0.874]	0.37 [0.26–0.49] pg/mL	0.24 [0.16–0.35] pg/mL	<0.001
IL-16	0.727 [0.642–0.813]	146.17 [107.02–309.52] pg/mL	110.04 [98.74–114.16] pg/mL	0.002

**Question:** What is the role of biomarkers in the evaluation and management of pts admitted to an ED for mTBI?



R2.2.1 - The experts suggest to use blood-based assay of **protein S100B**, when it is available, **during the 3 hrs following mild TBI**, in pts at intermediate risk, the objective being to limit the number of brain scans.

EXPERT OPINION (**STRONG AGREEMENT**)

R2.2.2 - The experts suggest to use blood-based assay combining **UCH-L1 and GFAP**, when they are available, **during the 12 hrs following mild TBI**, in pts at intermediate risk, the objective being to limit the number of brain scans.

EXPERT OPINION (**STRONG AGREEMENT**)





# Argumentation

*Amoo et al.*, (**meta-analysis**) serum GFA with a threshold of 22 pg/mL detects TBI by CT scan with a SE 93% [73–99], SP 36% [12–68].


*Rogan et al.*, (meta-analysis: **6 studies**) ) the diagnostic accuracy of serum GFAP **in** detecting intracranial lesions; SE 67% to 100% and SP 0% to 89%, while the NPV of GFAP ranged from 72.1% to 100%. For serum UCH-L1, (**4 studies**) SE 61% – 100%, and SP 21% – 63.7% with NPV to rule out a lesion by CT scan 70.7% to 100%.

A combination of UCH-L1 and GFAP serum (**1 study**) <12 hrs from trauma, at thresholds of 327 pg/mL and 22 pg/mL, **rules out an intracranial lesion** (SP 36.7% [34.5–39.0], **SE 97.3%** [92.4–99.4], NPV 99.5% [98.7– 99.9]).



# Traumatismo craneoencefálico leve y biomarcadores de lesión cerebral aguda

Francisco Tembory Ruiz<sup>1</sup>, Francisco Moya Torrecilla<sup>2</sup>, Miguel Ángel Arráez Sánchez<sup>3</sup>, Ignacio Arribas Gómez<sup>4</sup>, Agustina Vicente Bártulos<sup>5</sup>, Francisco José Gallego España<sup>6</sup>, Miriam Menacho Román<sup>7</sup>, Audrey Morales Rodríguez<sup>8</sup>, Daniel Morell-García<sup>9</sup>, Inés Pecharromán de las Heras<sup>10</sup>, José Roberto Penedo Alonso<sup>11</sup>, José Antonio Prieto Arruñada<sup>12</sup>, Fernando Rosell Ortiz<sup>13</sup>, Carlos Sánchez Rodríguez<sup>14</sup>



## MANEJO HOSPITALARIO TCE LEVE

\*GFAP: proteína ácida fibrilar glial;  
 UCH-L1: ubiquitina C-terminal hidrolasa-L1

# Take home

- Il test diagnostico di riferimento resta la diagnostica per immagini (TC cranio encefalo).
- Le LG attuali si basano su elementi clinici ad un TC rate 50-70%, accuratezza 90-92% (falsi negativi 0.3% ???).
- I marcatori nei casi a basso rischio (asintomatici) potrebbero aggiungere elementi decisionali, anche se mancano dati solidi.
- I marcatori potrebbero migliorare l'appropriatezza degli esami TC, (riduzione di costi e radio-esposizione per quel 90% dei casi negativi).
- La qualità degli studi e il grado delle raccomandazione ad oggi sono ancora di basso grado.



XIII congresso nazionale

**simeu**

GENOVA 30 MAG - 1 GIU 2024

